Paraproteinemias
Information
- Disease name
- Paraproteinemias
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04309084 | Active, not recruiting | Phase 1 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | May 12, 2020 | April 30, 2023 |
| NCT01755000 | Completed | N/A | Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings | December 2012 | April 2013 |
| NCT02033928 | Completed | Comprehensive Frailty Assessment | April 2014 | August 2017 | |
| NCT00001287 | Completed | Phase 2 | Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | December 1990 | January 2001 |
| NCT05147493 | Not yet recruiting | Phase 2 | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | April 2022 | February 2025 |
| NCT05298683 | Not yet recruiting | Phase 2 | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | May 2022 | January 2026 |
| NCT05581875 | Not yet recruiting | Phase 1/Phase 2 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | October 20, 2022 | October 31, 2026 |
| NCT05280275 | Recruiting | Phase 1/Phase 2 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | April 13, 2022 | March 15, 2026 |
| NCT06271252 | Recruiting | Phase 1 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | April 3, 2024 | April 12, 2028 |
| NCT05573802 | Recruiting | Phase 1/Phase 2 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | July 14, 2023 | October 31, 2026 |
| NCT02462213 | Withdrawn | Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging | October 2013 | December 2017 | |
| NCT02155634 | Withdrawn | Phase 3 | Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | July 2014 | March 2021 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D010265